I-Mab stops work on CD73; Citius to pursue ‘strategic’ options

Plus, news about Gen­er­al Prox­im­i­ty and PBS Biotech:

I-Mab paus­es CD73 de­vel­op­ment: The com­pa­ny is not mov­ing for­ward with a pro­gram …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.